Yes not much Arrow shareholders can do, except the following....

Yes not much Arrow shareholders can do, except the following. Not sure how much affect it will have on the proposed merger, but I would suggest the following:

1) Vote against a change in name from Arrow Pharmaceuticals to Sigma Pharmaceuticals, or similar

2) Vote against an increase in non-executive directors fees

3) Don't approve the issue of 550k of options and 4.4mill performance rights to De Alwis.

Probably be more of a hindrance than anything if the above was successful. I still can't believe that AWP have agreed to this price. Must be a whole lot in it for the management of AWP.